<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683640</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202000105-N</org_study_id>
    <secondary_id>P30AG059297</secondary_id>
    <nct_id>NCT04683640</nct_id>
  </id_info>
  <brief_title>Latent Aging Mechanisms in Pain and Sleep</brief_title>
  <acronym>LAMPS</acronym>
  <official_title>Sleep, Pain and Aging: Potential Underlying Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thorne Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic pain is a serious public health problem in older adults depending on the pain&#xD;
      condition, and the capacity to sleep properly changes with age. Given the potential&#xD;
      mechanistic role of GABA in both conditions, based on our preliminary data, this proposal&#xD;
      will determine the effect of oral GABA administration in sleep quality and pain in older&#xD;
      adults with chronic pain and sleep disorders as well as to characterize the potential&#xD;
      neurobiological mechanisms involved in both illnesses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-Reported Sleep Quality Scoring</measure>
    <time_frame>Baseline up to 1 month</time_frame>
    <description>Self-Reported Sleep quality will be assessed with the Pittsburgh Sleep Quality Index (PSQI) and PSQI total score will be the primary sleep outcome measure to compare to sleep quality using objective and self-reported measures. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Daily Oral GABA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>You will take, by mouth, 2 pills of GABA (500 mg) (Capsule 250mg) daily at home for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>You will take, by mouth, 2 pills of Placebo daily at home for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GABA</intervention_name>
    <description>Daily oral GABA for 4 weeks</description>
    <arm_group_label>Daily Oral GABA</arm_group_label>
    <other_name>Gamma aminobutyric acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily oral Placebo for 4 weeks</description>
    <arm_group_label>Daily Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older adults over 65 years of age who experienced pain of at least moderate intensity&#xD;
             (&gt;5/10 pain intensity ratings) on more days than not during the past three months, and&#xD;
             who also reported poor sleep quality (&gt;5 PSQI scores) will be considered for&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious psychiatric conditions (e.g., schizophrenia, major depression, bipolar&#xD;
             disorder&#xD;
&#xD;
          -  History of alcohol/drug abuse&#xD;
&#xD;
          -  Alzheimer, Parkinson, Epilepsy and other known intracerebral pathology and&#xD;
             neurological conditions&#xD;
&#xD;
          -  Significant cognitive impairment as evidenced by the Modified Mini-Mental State&#xD;
             examination (3MS) score â‰¤ 77; 5) hospitalizations for mental health reasons in the&#xD;
             past year&#xD;
&#xD;
          -  Chronic/current use of narcotic medications&#xD;
&#xD;
          -  Serious systemic (uncontrolled diabetes self-reported HA1C&gt;7) and rheumatic disorders&#xD;
             (i.e., rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia, HIV)&#xD;
&#xD;
          -  arterial hypotension&#xD;
&#xD;
          -  Digestive tract diseases&#xD;
&#xD;
          -  Major medical surgery in the past two months&#xD;
&#xD;
          -  History of brain surgery or any serious brain condition like aneurysm, stroke, or&#xD;
             seizures;&#xD;
&#xD;
          -  Excessive anxiety regarding protocol procedures;&#xD;
&#xD;
          -  Inability to consent for study participation&#xD;
&#xD;
          -  Ingestion of sleep medications including those with zolpidem (Ambien and others) and&#xD;
             eszopiclone (Lunesta and others)&#xD;
&#xD;
          -  Neuropathic pain&#xD;
&#xD;
          -  Medications including anticonvulsants and antidepressants&#xD;
&#xD;
          -  Hypertension medications&#xD;
&#xD;
          -  Allergies or sensitivity to GABA or its ingredients cellulose' gelatin (capsule)'&#xD;
             magnesium silicate' vegetable stearate and silica or to the placebo or its&#xD;
             ingredients: calcium laurate, hypromellose capsule, magnesium (citrate),&#xD;
             microcrystalline cellulose&#xD;
&#xD;
          -  Currently taking barbiturate and benzodiazepine and baclofen&#xD;
&#xD;
          -  MRI contraindications including large pieces of metal in the body/face/neck and&#xD;
             claustrophobia&#xD;
&#xD;
          -  Current cancer diagnosis unless determined no evidence of disease or in remission for&#xD;
             at least two years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yenisel Cruz-Almeida, MSPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Griffith</last_name>
    <phone>352-273-5979</phone>
    <email>ben.griffith@ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Griffith</last_name>
      <phone>352-273-5979</phone>
      <email>ben.griffith@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Yenisel Cruz-Almeida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

